NLRP3 Inhibitor Salt Formulation for Autoinflammatory Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoinflammatory disorders such as CAPS, TRAPS, FMF, Behcet Disease, and others are inadequate in effectively managing inflammation due to the aberrant activity of NLRP3, which is implicated in these conditions, and existing therapies may not fully inhibit NLRP3 activity.
Innovation Solution
A compound of formula (I) or its pharmaceutically acceptable salt, particularly in the form of a crystalline monosodium monohydrate salt, is administered orally to inhibit NLRP3 activity, reducing inflammation in autoinflammatory disorders, with specific dosing regimens and formulations optimized for effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat autoinflammatory disorders, then treatment is provided, but NLRP3 activity is not fully inhibited and inflammation is not effectively managed
Solution Approach 1:
The patent modifies the chemical structure parameters of existing NLRP3 inhibitors to create compound (I) with optimized pharmacological properties. This includes adjusting molecular weight, lipophilicity, and binding affinity parameters to achieve complete NLRP3 inhibition while maintaining safety, thereby resolving the contradiction between effective treatment and full NLRP3 inhibition.
Solution Approach 2:
The patent develops a composite pharmaceutical formulation containing compound (I) in specific salt forms (such as monosodium salt) combined with optimized excipients. This composite approach enhances the drug's solubility, stability, and bioavailability, enabling complete NLRP3 inhibition while ensuring effective delivery and treatment reliability.
2Ease of operation
If compound (I) is administered orally, then treatment convenience is improved, but bioavailability and efficacy must be maintained
Solution Approach 1:
The patent optimizes compound (I) for oral administration by adjusting key pharmacokinetic parameters including oral bioavailability, gastrointestinal stability, and metabolic resistance. The compound is designed with appropriate lipophilicity and molecular properties to ensure adequate absorption through the gastrointestinal tract while maintaining complete NLRP3 inhibition efficacy.
Solution Approach 2:
The patent employs specific salt forms of compound (I), particularly the monosodium salt, as intermediary compounds that enhance oral bioavailability. These salt forms improve solubility and dissolution rate in the gastrointestinal environment, acting as mediators that enable effective oral delivery while maintaining the parent compound's NLRP3 inhibitory activity.
Data Source
AI summary
The present invention relates to a compound of formula (I) for use in the treatment or prevention of an autoinflammatory disorder such as cryopyrin-associated periodic syndrome (CAPS), tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial mediterranean fever (FMF), Behcet Disease, Pyoderma Gangraenosum, systemic onset of juvenile idiopathic arthritis (sJIA), Schnitzler syndrome, or Hidradenitis Suppurativa.